Melinta and Cidara Ink Licensing Deal for Antifungal Drug

Melinta Therapeutics has secured the U.S. rights to Cidara Therapeutics’ investigational antifungal drug rezafungin with a $30 million upfront payment.

The licensing deal follows Cidara’s New Drug Application (NDA) submission to the FDA for rezafungin for treatment of patients with candidemia and invasive candidiasis.

The drug candidate is also being developed for the prophylaxis of invasive fungal infections in adult patients undergoing allogeneic blood and marrow transplantation.

In addition to a $30 million upfront payment, San Diego, Calif.-based Cidara is also eligible for up to $430 million for achieving regulatory and commercial milestones.